A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation

B. A. Mueller, Douglas Rex, N. Figueroa, P. Greene, D. C. Brater

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect. Ten healthy subjects received 20 mg piroxicam daily in a double-blind, randomized, crossover, placebo-controlled study. Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study. Pharmacokinetic data obtained included serum and gastric piroxicam concentrations and serum 5'-hydroxypiroxicam metabolite concentrations after the first dose and 2 weeks of dosing. No differences in endoscopy scores or patient symptom scores were noted between the two dosage forms after 2 weeks of dosing. Pharmacokinetic data of piroxicam and the metabolite revealed that the buccal formulation may not have been absorbed exclusively from the buccal mucosa.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalPharmacotherapy
Volume12
Issue number2 I
StatePublished - 1992

Fingerprint

Piroxicam
Cheek
Pharmacokinetics
Endoscopy
Dosage Forms
Mouth Mucosa
Serum
Capsules
Stomach
Healthy Volunteers
Arm
Anti-Inflammatory Agents
Placebos
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Mueller, B. A., Rex, D., Figueroa, N., Greene, P., & Brater, D. C. (1992). A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. Pharmacotherapy, 12(2 I), 93-97.

A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. / Mueller, B. A.; Rex, Douglas; Figueroa, N.; Greene, P.; Brater, D. C.

In: Pharmacotherapy, Vol. 12, No. 2 I, 1992, p. 93-97.

Research output: Contribution to journalArticle

Mueller, BA, Rex, D, Figueroa, N, Greene, P & Brater, DC 1992, 'A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation', Pharmacotherapy, vol. 12, no. 2 I, pp. 93-97.
Mueller, B. A. ; Rex, Douglas ; Figueroa, N. ; Greene, P. ; Brater, D. C. / A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation. In: Pharmacotherapy. 1992 ; Vol. 12, No. 2 I. pp. 93-97.
@article{a84a84daf5a04250948a573e3b1b9186,
title = "A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation",
abstract = "We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect. Ten healthy subjects received 20 mg piroxicam daily in a double-blind, randomized, crossover, placebo-controlled study. Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study. Pharmacokinetic data obtained included serum and gastric piroxicam concentrations and serum 5'-hydroxypiroxicam metabolite concentrations after the first dose and 2 weeks of dosing. No differences in endoscopy scores or patient symptom scores were noted between the two dosage forms after 2 weeks of dosing. Pharmacokinetic data of piroxicam and the metabolite revealed that the buccal formulation may not have been absorbed exclusively from the buccal mucosa.",
author = "Mueller, {B. A.} and Douglas Rex and N. Figueroa and P. Greene and Brater, {D. C.}",
year = "1992",
language = "English",
volume = "12",
pages = "93--97",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2 I",

}

TY - JOUR

T1 - A pharmacokinetic and endoscopic comparison of an oral and an experimental buccal piroxicam formulation

AU - Mueller, B. A.

AU - Rex, Douglas

AU - Figueroa, N.

AU - Greene, P.

AU - Brater, D. C.

PY - 1992

Y1 - 1992

N2 - We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect. Ten healthy subjects received 20 mg piroxicam daily in a double-blind, randomized, crossover, placebo-controlled study. Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study. Pharmacokinetic data obtained included serum and gastric piroxicam concentrations and serum 5'-hydroxypiroxicam metabolite concentrations after the first dose and 2 weeks of dosing. No differences in endoscopy scores or patient symptom scores were noted between the two dosage forms after 2 weeks of dosing. Pharmacokinetic data of piroxicam and the metabolite revealed that the buccal formulation may not have been absorbed exclusively from the buccal mucosa.

AB - We compared the endoscopic effects and pharmacokinetic profiles of an experimental buccal formulation of piroxicam to oral capsules in an attempt to determine whether nonsteroidal antiinflammatory drug-induced gastropathy is due to a local or systemic effect. Ten healthy subjects received 20 mg piroxicam daily in a double-blind, randomized, crossover, placebo-controlled study. Upper endoscopies were performed at the baseline and at the end of each 2-week dosing arm of the study. Pharmacokinetic data obtained included serum and gastric piroxicam concentrations and serum 5'-hydroxypiroxicam metabolite concentrations after the first dose and 2 weeks of dosing. No differences in endoscopy scores or patient symptom scores were noted between the two dosage forms after 2 weeks of dosing. Pharmacokinetic data of piroxicam and the metabolite revealed that the buccal formulation may not have been absorbed exclusively from the buccal mucosa.

UR - http://www.scopus.com/inward/record.url?scp=0026769846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026769846&partnerID=8YFLogxK

M3 - Article

C2 - 1570233

AN - SCOPUS:0026769846

VL - 12

SP - 93

EP - 97

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2 I

ER -